Repros Therapeutics (RPRX) Shares Bounce on Proellex Results
Tweet
Share
E-mailGet Alerts RPRX Hot Sheet
Join SI Premium – FREE
Repros Therapeutics (Nasdaq: RPRX) saw a little bounce today, following an announcement that it has completed its internal review of the results obtained for the 1 mg dose from its low dose study of Proellex, and no signals of liver toxicity or drug related adverse events were detected over the 10 week dosing period.
Shares are currently trading 7.8% lower this morning.
Click here for more color.
Shares are currently trading 7.8% lower this morning.
Click here for more color.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Royalty Pharma (RPRX) PT Raised to $65 at TD Cowen
- FDA approves Leqembi Iqlik subcutaneous injection for Alzheimer's
- INmune Bio publishes preclinical study on XPro1595 and brain injury
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
